Table 3.
Univariate and multivariable analyses of overall survival
| Univariate | Multivariable | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | |
| Age (yr) | 1.02 | 0.99–1.06 | 0.182 | |||
| Sex (male vs. female) | 0.79 | 0.40–1.53 | 0.467 | |||
| ECOG performance status (1 vs. 0) | 1.56 | 0.76–3.20 | 0.225 | |||
| Disease extent (BRPC vs. LAPC) | 1.20 | 0.37–3.96 | 0.761 | |||
| Tumor location (head vs. other) | 1.30 | 0.67–2.54 | 0.442 | |||
| Induction CT duration (mo) | 0.79 | 0.60–1.04 | 0.094 | 0.75 | 0.57–0.99 | 0.048 |
| Induction CT (FFX vs. GnP) | 0.67 | 0.26–1.76 | 0.417 | |||
| Grade (I/II vs. III) | 0.92 | 0.44–1.93 | 0.831 | |||
| Resected (yes vs. no) | 0.66 | 0.34–1.29 | 0.229 | |||
| CTV (cm3) | 1.01 | 0.99–1.01 | 0.051 | |||
| Baseline CA19-9 (U/mL) | 1.00 | 0.99–1.00 | 0.309 | |||
| Pre-SBRT CA19-9 (U/mL) | 1.001 | 1.000–1.001 | 0.031 | |||
| Baseline total bilirubin (mg/dL) | 1.08 | 0.96–1.17 | 0.173 | |||
| Pre-SBRT | ||||||
| ALC (×103/μL) | 0.66 | 0.34–1.13 | 0.140 | |||
| NLR | 1.04 | 0.94–1.10 | 0.354 | |||
| Post-SBRT | ||||||
| ALC (×103/μL) | 0.33 | 0.11–0.91 | 0.031 | |||
| NLR | 1.13 | 1.04–1.22 | 0.009 | 1.14 | 1.04–1.23 | 0.002 |
ECOG, Eastern Cooperative Oncology Group; BRPC, borderline resectable pancreatic cancer; LAPC, locally advanced pancreatic cancer; CT, chemotherapy; FFX, FOLFIRINOX; GnP, gemcitabine/nab-paclitaxel; CTV, Clinical target volume; CA19-9, cancer antigen 19-9; SBRT, stereotactic body radiation therapy; ALC, absolute lymphocyte count; ANC, absolute neutrophil count; NLR, neutrophil to lymphocyte ratio; HR, hazard ratio; CI, confidence interval.